N-[4-(3,5-dichloro-4-ethoxyphenyl)-1,3-thiazol-2-yl]-2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: N-[4-(3,5-dichloro-4-ethoxyphenyl)-1,3-thiazol-2-yl]-2-(4,6-dimethyl-5,7-dioxopyrazolo[4,3-d]pyrimidin-1-yl)acetamide
• 化学式: C₂₀H₁₈Cl₂N₆O₄S
• 分子量: 509.4
• InChiKey: VQQIZIMKKRZFEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  138
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID
  申请人：Khairatakar-Joshi Neelima

  公开号：US20140148423A1

  公开（公告）日：2014-05-29

  The present patent application relates to a pharmaceutical composition comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist and a glucocorticoid.
• PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND AN ANTICHOLINERGIC AGENT
  申请人：GLENMARK PHARMACEUTICALS S.A.

  公开号：US20140364445A1

  公开（公告）日：2014-12-11

  The present invention relates to a pharmaceutical composition comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist and an anticholinergic agent. Particularly, the present invention provides a pharmaceutical composition comprising a TRPA1 antagonist having IC 50 for inhibiting human TRPA1 receptor activity of less than 1 micromolar and an anticholinergic agent; a process for preparing such composition; and its use in treating a respiratory disorder in a subject.